{
    "symbol": "BSX",
    "quarter": 2,
    "year": 2022,
    "date": "2022-07-27 11:42:02",
    "content": " We expect full year 2022 operational revenue growth to be in a range of 10.5% to 11.5% versus 2021, which excludes an approximate 400 basis point headwind from foreign exchange based on current rates, 200 basis points higher than our previous expectations and includes a 250 basis point contribution from the acquisitions of Preventice, FARAPULSE, Lumenis and Baylis and $13 million of predivestiture specialty pharmaceutical sales in 2021. We expect third quarter 2022 operational revenue growth to be in a range of 10% to 12% versus 2021, which excludes an approximate 400 basis point headwind from foreign exchange based on current rates, and includes a 200 basis point contribution from the acquisitions of FARAPULSE, Lumenis and Baylis."
}